nach oben

Digestive Diseases and Sciences

Erschienen in:

01.01.2008 | Original Paper

Rifaximin versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBS

verfasst von: Janet Yang, Hyo-Rang Lee, Kimberly Low, Soumya Chatterjee, Mark Pimentel

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Previous studies demonstrate improvement in IBS after antibiotic therapy, with the greatest efficacy seen with the antibiotic, rifaximin. The purpose of this study was to compare the efficacy of rifaximin in both the treatment and retreatment of IBS.

Methods

A retrospective chart review was conducted on Rome I-positive IBS patients. Charts were reviewed to evaluate all antibiotic treatments (rifaximin, neomycin, doxycycline, amoxicillin/clavulanate, and ciprofloxacin), even those predating 1 July 2004. Data collection included symptoms, breath test results (pre- and post-treatment), antibiotics used, and clinical response to individual antibiotic treatments before and after rifaximin availability in the USA.

Results

Out of 98 eligible charts, 84 patients received one course of rifaximin. Fifty of these (60%) had a follow-up breath test. Among these, 31 (62%) were clinical responders and 19 (38%) were nonresponders. Of 31 responders, 25 (81%) had a normal follow-up breath test compared with only 3 of the 19 nonresponders (16%) (P < 0.001). Of participants given rifaximin, 69% (58 out of 84) had a clinical response compared with only 38% (9 out of 24) with neomycin (P < 0.01) and 44% (27 out of 61) with all non-rifaximin antibiotics (P < 0.01). Rifaximin was used as retreatment on 16 occasions, and all patients improved.

Conclusions

Rifaximin is more effective than other antibiotics in the treatment and retreatment of IBS.

Drossman DA (1994) The functional gastrointestinal disorders: diagnosis, pathophysiology, and treatment. A multinational consensus. Little, Brown, Boston

Drossman DA, Whitehead WE, Camilleri M (1997) Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 112:2120–2137PubMedCrossRef

Thompson WG, Heaton KW (1980) Functional bowel disorders in apparently healthy people. Gastroenterology 79:283–288PubMed

Kumar D, Wingate DL (1985) The irritable bowel syndrome: a paroxysmal motor disorder. Lancet 2:973–977PubMedCrossRef

Grundy D (2000) Mechanisms for the symptoms of irritable bowel disease—possible role of vagal afferents. In: Krammer H-J, Singer MV (eds) Neurogastroenterology from the basics to the clinics. Kluwer, Boston, pp 659–663

Silverman DHS, Munakata JA, Ennes H et al (1997) Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 112:64–72PubMedCrossRef

Whitehead WE, Crowell MD, Robinson JC et al (1992) Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut 33:825–830PubMedCrossRef

Thompson WG, Longstreth GF, Drossman DA et al (1999) Functional bowel disorders and functional abdominal pain. Rome II: a multinational consensus document on functional gastrointestinal disorders. Gut 45:1143–1147

Longstreth G, Thompson G, Chey W et al (2006) Functional bowel disorders. Gastroenterology 130:1480–1491PubMedCrossRef

10.

Holt PR (1990) Diarrhea and malabsorption in the elderly. Gastroenterol Clin North Am 19:345–359PubMed

11.

Pimentel M, Chow EJ, Lin HC (2000) Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95:3503–3506PubMedCrossRef

12.

Pimentel M, Chow EJ, Lin HC (2003) Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98:412–418PubMed

13.

Lupascu A, Gabrielli M, Lauritano EC et al (2005) Hydrogen glucose breath test to detect bacterial overgrowth: a prevalence case–control study in irritable bowel syndrome. Aliment Pharmacol Ther 22:1157–1160PubMedCrossRef

14.

McCallum R, Schultz C, Sostarich S (2005) Evaluating the role of small intestinal bacterial overgrowth (SIBO) in diarrhea predominant irritable bowel syndrome (IBS-D) patients utilizing the glucose breath test (GBT). Gastroenterology 128:A460

15.

Posserud I, Stotzer PO, Einar S et al (2006) Altered counts of small bowel bacteria in patients with irritable bowel syndrome. Gastroenterol 130:A739

16.

Drude RB, Finkelman D, Davis WD et al (1980) Malabsorption in jejunal diverticulosis treated with resection of the diverticula. Dig Dis Sci 25:802–806PubMedCrossRef

17.

Soudah HC, Hasier WL, Owyang C (1991) Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 325:1461–1467PubMedCrossRef

18.

Di Stefano M, Malservisi S, Veneto G et al (2000) Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 14:551–556PubMedCrossRef

19.

Attar A, Flourie B, Rambaud JC et al (1999) Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 117:794–797PubMedCrossRef

20.

Scarpignato C, Pelosini I (2005) Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 51:S36–S66CrossRef

21.

Sharara AI, Aoun E, Abdul-Baki H et al (2006) A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101:326–333PubMedCrossRef

22.

Pimentel M, Park S, Kong Y, Kane SV (2006) Rifaximin, a non-absorbable antibiotic improves the symptoms of irritable bowel syndrome: a double-blind randomized controlled study. Ann Intern Med 145:557–563PubMed

23.

Nucera G, Gabrielli M, Lupascu A et al (2005) Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 21:1391–1395PubMedCrossRef

24.

Simren M, Ringstrom G, Agerforz P et al (2003) Small intestinal bacterial overgrowth is not of major importance in irritable bowel syndrome. Gastroenterology 124:A163CrossRef

25.

Robson KM, Kakullavarapu J, Lembo T (2003) Bacterial overgrowth and irritable bowel syndrome: a look at prevalence, symptoms and quality of life. Am J Gastroenterol 98:S271CrossRef

26.

Singh VV, Toskes PP (2004) Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Treat Options Gastroenterol 7:19–28PubMedCrossRef

27.

Hoover W, Gerlach E, Hoban D et al (1993) Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diag Microbiol Infect Dis 16:111–118CrossRef

28.

Gillis JC, Brogden RN (1995) Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 49:467–484PubMedCrossRef

29.

DuPont HL, Jiang ZD, Okhuysen PC et al (2005) A randomized, double-blind, placebo-controlled trial of rifaximin to prevent traveler’s diarrhea. Ann Intern Med 142:805–812PubMed

30.

Mas A, Rodes J, Sunyer L et al (2003) Spanish association for the study of liver hepatic encephalopathy cooperative group. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double dummy, controlled clinical trial. J Hepatol 38:51–58PubMedCrossRef

31.

Gerard L, Garey KW, DuPont HL (2005) Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 3:201–211PubMedCrossRef

32.

DuPont HL (2003) Community-acquired diarrheal disease in western countries: application of nonabsorbable oral antibiotic therapy. Adv Stud Med 3:S945–S950

33.

Lauritano EC, Gabrielli M, Lupascu A et al (2005) Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 22:31–35PubMedCrossRef

Titel: Rifaximin versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBS
verfasst von: Janet Yang
Hyo-Rang Lee
Kimberly Low
Soumya Chatterjee
Mark Pimentel
Publikationsdatum: 01.01.2008
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 1/2008
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-007-9839-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Rifaximin versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBS

Abstract

Purpose

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Proteome Analysis of Human Pancreatic Ductal Adenocarcinoma Tissue Using Two-Dimensional Gel Electrophoresis and Tandem Mass Spectrometry for Identification of Disease-Related Proteins

Pneumatosis Intestinalis and Portal Venous Gas Without Bowel Ischemia in a Patient Treated with Irinotecan and Cisplatin

Chronic Hepatitis C Virus and Celiac Disease, is there an Association?

Protective Roles of α-Calcitonin and β-Calcitonin Gene-Related Peptide in Spontaneous and Experimentally Induced Colitis

The Effect of Restraint Stress on the Normal Colon and on Intestinal Inflammation in a Model of Experimental Colitis

The Diagnostic Yield of Various Tests for Helicobacter pylori Infection in Patients on Acid-Reducing Drugs

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin